Aris Persidis ^UDM

Aris Persidis is a seasoned entrepreneur in Biotech and Big Data, serving as the President and Co-founder of Biovista. With a track record of co-founding successful ventures, including Cellzome (acquired by GSK), Anadys (acquired by Roche), RheoGene (acquired by Intrexon), and being the Senior Vice President at Upstate (acquired by Serologicals), Aris brings extensive experience to Biovista. He also played a crucial role as the first Chairperson of the Jefferson Corner Group Fund I, an angel investor group in Charlottesville, VA. Aris, a Ph.D. holder in biochemistry from Cambridge, UK, has authored numerous papers and book chapters, serving as the first Editor-in-Chief of the journal Drug Repurposing, Rescue, and Repositioning. He is a prominent figure in the biotechnology industry and has been recognized in the World's Top-50 Futurists. Biovista, under Aris's leadership, specializes in delivering custom drug repositioning, drug de-risking, and clinical hold solutions for the Biopharma Industry. The company is also involved in developing powerful platform technologies for Life Science and Biotechnology companies, with an ongoing commitment to R&D for innovation and improvement.